cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.12594290
title: Supplementary Material for: Proinflammatory α-Adrenergic Neuronal Regulation of Splenic IFN-γ, IL-6, and TGF-β of Mice from Day 15 onwards in Arthritis

description: <b><i>Introduction:</i></b> In arthritic mice, a sympathetic influence is proinflammatory from the time point of immunization until the onset of disease (days 0–32), but reasons are unknown. Disruption of the major anti-inflammatory pathway through G<sub>αs</sub>-coupled receptors probably play a role. For example, noradrenaline cannot operate via anti-inflammatory β<sub>2</sub>-adrenoceptors but through proinflammatory α<sub>1/2</sub>-ad­renoceptors. This might happen, first, through a loss of sympathetic nerve fibers in inflamed tissue with low neurotransmitter levels (noradrenaline only binds to high-affinity α-adrenoceptors) and, second, through an alteration in G-protein receptor coupling with a predominance of α-adrenergic signaling. We hypothesized that both mechanisms play a role in the course of collagen type II-induced arthritis (CIA) in the spleen in mice. <b><i>Methods:</i></b> In CIA mice, nerve fiber density in the spleen was quantified by immunohistochemistry techniques. The functional impact of sympathetic nerve fibers in the spleen was studied by a micro­superfusion technique of spleen slices with a focus on the secretion of IFN-γ and IL-6 (proinflammatory) and TGF-β (anti-inflammatory). <b><i>Results:</i></b> During CIA, sympathetic nerve fibers get increasingly lost from day14 until day 55 after immunization. The influence of electrically released noradrenaline diminishes in the course of arthritis. At all investigated time points (days 14, 32, and 55), only proinflammatory neuronal α-adrenergic effects on cytokine secretion were demonstrated (i.e., stimulation of IFN-γ and IL-6 and inhibition of TGF-β). <b><i>Conclusion:</i></b> Sympathetic nerve fibers are rapidly lost in the spleen, and only proinflammatory α-adrenergic neuronal regulation of cytokine secretion takes place throughout the course of arthritis. These results support a predominance of a proinflammatory α-adrenergic sympathetic influence in arthritis.
DOI: 10.6084/m9.figshare.12594239.v1
title: Supplementary Material for: Semaphorin-3C Is Upregulated in Polycystic Kidney Epithelial Cells and Inhibits Angiogenesis of Glomerular Endothelial Cells

description: <b><i>Background:</i></b> Polycystic kidney disease (PKD) is a hereditary disease characterized by cyst formation in the kidneys bilaterally. It has been observed that semaphorin-3C (SEMA3C) is overexpressed in polycystic kidney epithelial cells. It is hypothesized that upregulated SEMA3C would contribute to survival of polycystic kidney epithelial cells. Furthermore, as the kidney is a highly vascularized organ, the secreted SEMA3C from PKD epithelial cells will affect glomerular endothelial cells (GECs) in a paracrine manner. <b><i>Methods:</i></b> To evaluate the effect of SEMA3C on renal cells, siSEMA3C-treated PKD epithelial cells were used for further analysis, and GECs were exposed to recombinant SEMA3C (rSEMA3C). Also, co-culture and treatment of conditioned media were employed to confirm whether PKD epithelial cells could influence on GECs via SEMA3C secretion. <b><i>Results:</i></b> SEMA3C knockdown reduced proliferation of PKD epithelial cells. In case of GECs, exposure to rSEMA3C decreased angiogenesis, which resulted from suppressed migratory ability not cell proliferation. <b><i>Conclusions:</i></b> This study indicates that SEMA3C is the aggravating factor in PKD. Thus, it is proposed that targeting SEMA3C can be effective to mitigate PKD.
DOI: 10.6084/m9.figshare.12594377.v1
title: Dataset Secondhand smoking and preterm birth

description: Dataset for SHS preterm
DOI: 10.6084/m9.figshare.12594149
title: Supplementary Material for: Histologic and Clinical Effects of Different Topical Corticosteroids for Eosinophilic Esophagitis: Lessons from an Updated Meta-Analysis of Placebo-Controlled Randomized Trials

description: <b><i>Background:</i></b> Topical corticosteroids (TS) have become standard therapy for eosinophilic esophagitis (EoE). However, a variety of drug formulations have been used for which results of histological and clinical responses may be different. We aimed at determining the short-term histologic efficacy of TS for EoE based on randomized placebo-controlled trials and to review clinical response. <b><i>Methods:</i></b> We searched MEDLINE, ISI Web of Science, and clinicaltrials.gov for randomized controlled trials (RCTs) on TS versus placebo for active EoE published until June 2019. Treatment effects were calculated as risk ratios (RRs) comparing histologic remission between groups. <b><i>Results:</i></b> Nine RCTs (6 budesonide and 3 fluticasone) involving a total of 483 participants were included. A substantial overall effect of TS on acute histologic remission (RR 12.5, 95% confidence interval 6.0–25.9) was found despite varying definitions of histologic response. Indirect comparisons between drug and formulation types showed a trend for a better histologic efficacy of budesonide (RR 13.5 vs. 10.4 fluticasone) and for the orodispersible tablet (RR 46.2 vs. 11.5 suspension, and 10.4 nebulized formula/spray), but only based on small patient numbers. Scores used for clinical response assessment were different between studies, and short-term clinical results were less impressive: significant differences favoring TS were found in 4/9 RCTs (4/6 budesonide, 0/3 fluticasone). <b><i>Conclusions:</i></b> TS are effective for short-term induction of histological remission in EoE with less impressive clinical response rates. The mode of drug delivery to the esophagus may be a relevant factor for the degree of histologic remission. Further trials should use uniform assessment criteria and long-term patient-centered outcomes.
DOI: 10.6084/m9.figshare.12594140
title: PLSDB 2020_06_29

description: PLSDB files from 2020.06.29
DOI: 10.6084/m9.figshare.12594377.v2
title: Secondhand smoking and preterm birth

description: Dataset for SHS preterm
DOI: 10.6084/m9.figshare.12593918
title: Madsen Supplemental Table 3

description: Supplemental Table 3. Reference intervals in for Tanner and US breast stages: Conventional units<br>Sample size (No.) and analyte levels corresponding to the median and resampled 95% reference intervals are presented for indicated puberty breast stage partitions. Column “Z” summarizes Harris-Boyd standard deviate tests to determine justified partitioning of current and the previous partition (ayes) or not (n.s., not significant). Abbreviations: B, Tanner breast stage; E1, estrone; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin; US B, ultrasound breast stage.
DOI: 10.6084/m9.figshare.12593918.v1
title: Madsen Supplemental Table 3

description: Supplemental Table 3. Reference intervals in for Tanner and US breast stages: Conventional units<br>Sample size (No.) and analyte levels corresponding to the median and resampled 95% reference intervals are presented for indicated puberty breast stage partitions. Column “Z” summarizes Harris-Boyd standard deviate tests to determine justified partitioning of current and the previous partition (ayes) or not (n.s., not significant). Abbreviations: B, Tanner breast stage; E1, estrone; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin; US B, ultrasound breast stage.
DOI: 10.6084/m9.figshare.12593912
title: Madsen Supplemental Table 2

description: Nonparametric 95% reference intervals for indicated hormones according to female chronological age (1-year increments) interpolated from panels in manuscript Figure 2. Upper and lower limits were not interpolated where the number of biological observations in that range was less than 120. Abbreviations: E1, estrone; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
DOI: 10.6084/m9.figshare.12593912.v1
title: Madsen Supplemental Table 2

description: Nonparametric 95% reference intervals for indicated hormones according to female chronological age (1-year increments) interpolated from panels in manuscript Figure 2. Upper and lower limits were not interpolated where the number of biological observations in that range was less than 120. Abbreviations: E1, estrone; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
DOI: 10.6084/m9.figshare.12593762
title: Madsen Supplemental Table 1

description: Nonparametric 95% reference intervals for indicated hormones according to female chronological age (1-year increments) interpolated from panels in manuscript Figure 2. Upper and lower limits were not interpolated where the number of biological observations in that range was less than 120. Abbreviations: E1, estrone; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
DOI: 10.6084/m9.figshare.12593756
title: Supplementary Material for: Three-Dimensional Imaging of Intraplaque Neovascularization in a Mouse Model of Advanced Atherosclerosis

description: Multiple lines of evidence suggest that intraplaque (IP) neovascularization promotes atherosclerotic plaque growth, destabilization, and rupture. However, pharmacological inhibition of IP neovascularization remains largely unexplored due to the limited number of animal models that develop IP neovessels and the lack of reliable methods for visualizing IP angiogenesis. Here, we applied 3D confocal microscopy with an optimized tissue-clearing process, immunolabeling-enabled three-dimensional imaging of solvent-cleared organs, to visualize IP neovessels in apolipoprotein E-deficient (ApoE<sup>−/−</sup>) mice carrying a heterozygous mutation (C1039+/−) in the fibrillin-1 gene. Unlike regular ApoE<sup>−/−</sup> mice, this mouse model is characterized by the presence of advanced plaques with evident IP neovascularization. Plaques were stained with antibodies against endothelial marker CD31 for 3 days, followed by incubation with fluorescently labeled secondary antibodies. Subsequent tissue clearing with dichloromethane (DCM)/methanol, DCM, and dibenzyl ether allowed easy visualization and 3D reconstruction of the IP vascular network while plaque morphology remained intact.
DOI: 10.6084/m9.figshare.12593756.v1
title: Supplementary Material for: Three-Dimensional Imaging of Intraplaque Neovascularization in a Mouse Model of Advanced Atherosclerosis

description: Multiple lines of evidence suggest that intraplaque (IP) neovascularization promotes atherosclerotic plaque growth, destabilization, and rupture. However, pharmacological inhibition of IP neovascularization remains largely unexplored due to the limited number of animal models that develop IP neovessels and the lack of reliable methods for visualizing IP angiogenesis. Here, we applied 3D confocal microscopy with an optimized tissue-clearing process, immunolabeling-enabled three-dimensional imaging of solvent-cleared organs, to visualize IP neovessels in apolipoprotein E-deficient (ApoE<sup>−/−</sup>) mice carrying a heterozygous mutation (C1039+/−) in the fibrillin-1 gene. Unlike regular ApoE<sup>−/−</sup> mice, this mouse model is characterized by the presence of advanced plaques with evident IP neovascularization. Plaques were stained with antibodies against endothelial marker CD31 for 3 days, followed by incubation with fluorescently labeled secondary antibodies. Subsequent tissue clearing with dichloromethane (DCM)/methanol, DCM, and dibenzyl ether allowed easy visualization and 3D reconstruction of the IP vascular network while plaque morphology remained intact.
DOI: 10.6084/m9.figshare.12593762.v1
title: Madsen Supplemental Table 1

description: Nonparametric 95% reference intervals for indicated hormones according to female chronological age (1-year increments) interpolated from panels in manuscript Figure 2. Upper and lower limits were not interpolated where the number of biological observations in that range was less than 120. Abbreviations: E1, estrone; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
DOI: 10.6084/m9.figshare.12593735
title: Metadata record for: High resolution monthly precipitation and temperature timeseries for the period 2006-2100

description: This dataset contains key characteristics about the data described in the Data Descriptor High resolution monthly precipitation and temperature timeseries for the period 2006-2100. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format
DOI: 10.6084/m9.figshare.12593735.v1
title: Metadata record for: High resolution monthly precipitation and temperature timeseries for the period 2006-2100

description: This dataset contains key characteristics about the data described in the Data Descriptor High resolution monthly precipitation and temperature timeseries for the period 2006-2100. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format
DOI: 10.6084/m9.figshare.12593741
title: Supplementary Material for: Epidemiology, Clinical Features, and Use of Early Supportive Measures in PHACE Syndrome: A European Multinational Observational Study

description: <b><i>Background:</i></b> PHACE syndrome is a rare inborn condition characterized by large facial hemangiomas and variable malformations of the arterial system, heart, central nervous system, and eyes. According to Orphanet estimates, the prevalence is &lt;1.0 per million. Data from Europe are limited to small case series, and there are no population-based data available. <b><i>Objectives:</i></b> We conducted the present study to provide population-based estimates of the disease prevalence of PHACE syndrome in children in Germany, Switzerland, and Austria. We compared these first systematic data on PHACE syndrome from Europe to published data from the PHACE Syndrome International Clinical Registry and Genetic Repository (USA). Clinical features in our cohort with PHACE syndrome were assessed in detail, including the need for early supportive measures. <b><i>Methods:</i></b> We used a population-based approach by means of a previously well-established network of child neurologists from Germany, Switzerland, and Austria (“ESNEK”) to identify potential patients. The patients’ guardians and child neurologists were asked to fill in questionnaires developed in collaboration with the International PHACE Registry. <b><i>Results:</i></b> We identified 19 patients with PHACE syndrome. Estimated prevalence rates were 6.5 per million in Switzerland, 0.59 per million in Germany, and 0.65 per million in Austria. A subset of 10 patients from Germany and Switzerland participated in our study, providing detailed clinical assessment (median age: 2.5 years; 9 females, 1 male). Cerebrovascular involvement was frequent (80%). Facial hemangioma extent correlated significantly with the number of organs involved (<i>p</i> = 0.011). In 9 out of 10 patients, facial hemangiomas were treated successfully with oral propranolol. Baseline demographic data as well as the rate of cerebrovascular and cardiovascular anomalies were in line with those from the US International PHACE Registry and other published PHACE cohorts. <b><i>Conclusions:</i></b> Our study provides population-based estimates for PHACE syndrome in 3 German-speaking countries. The data from Switzerland indicate that PHACE syndrome may be more prevalent than demonstrated by previous reports. Underreporting of PHACE syndrome in Germany and Austria likely accounts for the differences in prevalence rates. The clinical observation of a potential association between the size of facial hemangioma and extent of organ involvement warrants further investigation.
DOI: 10.6084/m9.figshare.12593741.v1
title: Supplementary Material for: Epidemiology, Clinical Features, and Use of Early Supportive Measures in PHACE Syndrome: A European Multinational Observational Study

description: <b><i>Background:</i></b> PHACE syndrome is a rare inborn condition characterized by large facial hemangiomas and variable malformations of the arterial system, heart, central nervous system, and eyes. According to Orphanet estimates, the prevalence is &lt;1.0 per million. Data from Europe are limited to small case series, and there are no population-based data available. <b><i>Objectives:</i></b> We conducted the present study to provide population-based estimates of the disease prevalence of PHACE syndrome in children in Germany, Switzerland, and Austria. We compared these first systematic data on PHACE syndrome from Europe to published data from the PHACE Syndrome International Clinical Registry and Genetic Repository (USA). Clinical features in our cohort with PHACE syndrome were assessed in detail, including the need for early supportive measures. <b><i>Methods:</i></b> We used a population-based approach by means of a previously well-established network of child neurologists from Germany, Switzerland, and Austria (“ESNEK”) to identify potential patients. The patients’ guardians and child neurologists were asked to fill in questionnaires developed in collaboration with the International PHACE Registry. <b><i>Results:</i></b> We identified 19 patients with PHACE syndrome. Estimated prevalence rates were 6.5 per million in Switzerland, 0.59 per million in Germany, and 0.65 per million in Austria. A subset of 10 patients from Germany and Switzerland participated in our study, providing detailed clinical assessment (median age: 2.5 years; 9 females, 1 male). Cerebrovascular involvement was frequent (80%). Facial hemangioma extent correlated significantly with the number of organs involved (<i>p</i> = 0.011). In 9 out of 10 patients, facial hemangiomas were treated successfully with oral propranolol. Baseline demographic data as well as the rate of cerebrovascular and cardiovascular anomalies were in line with those from the US International PHACE Registry and other published PHACE cohorts. <b><i>Conclusions:</i></b> Our study provides population-based estimates for PHACE syndrome in 3 German-speaking countries. The data from Switzerland indicate that PHACE syndrome may be more prevalent than demonstrated by previous reports. Underreporting of PHACE syndrome in Germany and Austria likely accounts for the differences in prevalence rates. The clinical observation of a potential association between the size of facial hemangioma and extent of organ involvement warrants further investigation.
DOI: 10.6084/m9.figshare.12593618
title: Table 1. DMR-based topic modeling result (30 topics)

description: Table 1. DMR-based topic modeling result (30 topics)
DOI: 10.6084/m9.figshare.12593630
title: Supplementary Material for: Magnetic Resonance Spectroscopy following Mild Traumatic Brain Injury: A Systematic Review and Meta-Analysis on the Potential to Detect Posttraumatic Neurodegeneration

description: <b><i>Introduction:</i></b> Traumatic brain injury (TBI) is the most relevant external risk factor for dementia and a major global health burden. Mild TBI (mTBI) contributes to up to 90% of all TBIs, and the classification “<i>mild”</i> often misrepresents the patient’s burden who suffer from neuropsychiatric long-term sequelae. Magnetic resonance spectroscopy (MRS) allows in vivo detection of compromised brain metabolism although it is not routinely used after TBI. <b><i>Objective:</i></b> Thus, we performed a systematic review and meta-analysis to elucidate if MRS has the potential to identify changes in brain metabolism in adult patients after a single mTBI with a negative routine brain scan (CCT and/or MRI scan) compared to aged- and sex-matched healthy controls (HC) during the acute or subacute postinjury phase (≤90 days after mTBI). <b><i>Methods:</i></b> A comprehensive literature search was conducted from the first edition of electronic databases until January 31, 2020. Group analyses were performed per metabolite using a random-effects model. <b><i>Results:</i></b> Four and 2 out of 5,417 articles met the inclusion criteria for the meta-analysis and systematic review, respectively. For the meta-analysis, 50 mTBI patients and 51 HC with a mean age of 31 and 30 years, respectively, were scanned using <i>N</i>-acetyl-aspartate (NAA), a marker for neuronal integrity. Glutamate (Glu), a marker for disturbed brain metabolism, choline (Cho), a marker for increased cell membrane turnover, and creatine (Cr) were used in 2 out of the 4 included articles. Regions of interests were the frontal lobe, the white matter around 1 cm above the lateral ventricles, or the whole brain. NAA was decreased in patients compared to HC with an effect size (ES) of –0.49 (95% CI –1.08 to 0.09), primarily measured in the frontal lobe. Glu was increased in the white matter in 22 mTBI patients compared to 22 HC (ES 0.79; 95% CI 0.17–1.41). Cho was decreased in 31 mTBI patients compared to 31 HC (ES –0.31; 95% CI –0.81 to 0.19). Cr was contradictory and, therefore, potentially not suitable as a reference marker after mTBI. <b><i>Conclusions:</i></b> MRS pinpoints changes in posttraumatic brain metabolism that correlate with cognitive dysfunction and, thus, might possibly help to detect mTBI patients at risk for unfavorable outcome or posttraumatic neurodegeneration early.
DOI: 10.6084/m9.figshare.12593618.v1
title: Table 1. DMR-based topic modeling result (30 topics)

description: Table 1. DMR-based topic modeling result (30 topics)
DOI: 10.25377/sussex.12593567
title: Data for research article 'Establishment, spread and impact of an invasive planthopper on its invasive host plant: Prokelisia marginata (Homoptera: Delphacidae) exploiting Spartina anglica (Poales: Poaceae) in Britain'

description: <b>Data for paper published in Ecological Entomology July 2020</b><br><br>Data contains arthropod community composition observational surveys and impact of P. marginata colonisation on performance metrics of S. anglica host plants under field and glasshouse experimental conditions.<br>For details, please read the methods in the published paper.<br>Abstract 1. Since its recent arrival in Britain, the planthopper <i>Prokelisia marginata</i> has spread widely around saltmarshes on the east and south coast of England and south Wales, feeding on Common Cordgrass, <i>Spartina anglica</i>, itself an invasive non-native species. 2. Results suggest that <i>P. marginata</i> populations in Britain are benefitting from a degree of natural enemy release. No evidence of parasitism was found in over 71,000 eggs, nymphs and adults inspected. The only potential natural enemy control was suggested by a positive correlation between the densities of planthoppers and generalist spiders. 3. Experimental exposure under both glasshouse and field conditions to typical field densities of planthoppers resulted in significant negative effects on a number of host plant performance metrics. 4. <i>S. anglica</i> is important for stabilising estuarine sediments and has been deliberately planted for this purpose in the past. Its weakening as a result of heavy planthopper herbivory could have serious consequences for the long-term stability of Britain’s vulnerable saltmarsh habitats.<br><br><br>